KR102168738B1 - 히단토인 유도체 - Google Patents
히단토인 유도체 Download PDFInfo
- Publication number
- KR102168738B1 KR102168738B1 KR1020157017844A KR20157017844A KR102168738B1 KR 102168738 B1 KR102168738 B1 KR 102168738B1 KR 1020157017844 A KR1020157017844 A KR 1020157017844A KR 20157017844 A KR20157017844 A KR 20157017844A KR 102168738 B1 KR102168738 B1 KR 102168738B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- dione
- triazaspiro
- sulfonyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BPZXIMXHLOSTAF-UHFFFAOYSA-N CC1[N](C)(C)C1 Chemical compound CC1[N](C)(C)C1 BPZXIMXHLOSTAF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2012-269178 | 2012-12-10 | ||
| JP2012269178 | 2012-12-10 | ||
| PCT/JP2013/083022 WO2014092061A1 (ja) | 2012-12-10 | 2013-12-10 | ヒダントイン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150092275A KR20150092275A (ko) | 2015-08-12 |
| KR102168738B1 true KR102168738B1 (ko) | 2020-10-22 |
Family
ID=50934349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157017844A Expired - Fee Related KR102168738B1 (ko) | 2012-12-10 | 2013-12-10 | 히단토인 유도체 |
Country Status (34)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010126030A1 (ja) | 2009-04-28 | 2010-11-04 | 中外製薬株式会社 | スピロイミダゾロン誘導体 |
| NO2930176T3 (enrdf_load_stackoverflow) * | 2012-12-10 | 2018-07-07 | ||
| AU2014397042B2 (en) * | 2014-06-09 | 2020-04-09 | Chugai Seiyaku Kabushiki Kaisha | Hydantoin derivative-containing pharmaceutical composition |
| CA3107665A1 (en) | 2018-07-30 | 2020-02-06 | Chugai Seiyaku Kabushiki Kaisha | Solid dispersion of hydantoin derivative |
| CN110464002A (zh) * | 2019-09-12 | 2019-11-19 | 西南石油大学 | 一种天然冰粉的制备方法及其应用 |
| WO2024143501A1 (ja) | 2022-12-28 | 2024-07-04 | 中外製薬株式会社 | 分散対象物質を含む固体分散体、それを含む医薬組成物及びそれらの製造方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050101574A1 (en) | 2000-08-30 | 2005-05-12 | Seiichi Ishizuka | Parathyroid hormone production inhibitors containing vitamin d3 derivatives |
| WO2010126030A1 (ja) | 2009-04-28 | 2010-11-04 | 中外製薬株式会社 | スピロイミダゾロン誘導体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1135470A (ja) * | 1997-07-23 | 1999-02-09 | Teijin Ltd | ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤 |
| ES2249055T3 (es) | 1998-12-11 | 2006-03-16 | F. Hoffmann-La Roche Ag | Derivados de hidrazina. |
| US7004593B2 (en) * | 2002-06-06 | 2006-02-28 | Donnelly Corporation | Interior rearview mirror system with compass |
| SK4972003A3 (en) * | 2000-10-26 | 2004-05-04 | Pfizer Prod Inc | 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| WO2005077959A1 (en) * | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| WO2005077918A1 (en) * | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| US7659264B2 (en) | 2004-10-07 | 2010-02-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| WO2007135417A1 (en) | 2006-05-19 | 2007-11-29 | James Black Foundation | Benzotriazepinone derivatives |
| WO2007149873A2 (en) | 2006-06-20 | 2007-12-27 | Wyeth | Kv1.5 potassium channel inhibitors |
| JP2010529069A (ja) | 2007-06-07 | 2010-08-26 | エフ．ホフマン−ラ ロシュ アーゲー | Ｎｋ３アンタゴニストとしてのプロリンアミド誘導体 |
| MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| US8513193B2 (en) | 2008-10-13 | 2013-08-20 | University Of Rochester | Protecting and repairing cartilage and musculoskeletal soft tissues |
| NO2930176T3 (enrdf_load_stackoverflow) * | 2012-12-10 | 2018-07-07 | ||
| AU2014397042B2 (en) * | 2014-06-09 | 2020-04-09 | Chugai Seiyaku Kabushiki Kaisha | Hydantoin derivative-containing pharmaceutical composition |
-
2013
- 2013-12-10 NO NO13862318A patent/NO2930176T3/no unknown
- 2013-12-10 DK DK13862318.6T patent/DK2930176T3/en active
- 2013-12-10 MX MX2015007309A patent/MX2015007309A/es active IP Right Grant
- 2013-12-10 PL PL13862318T patent/PL2930176T3/pl unknown
- 2013-12-10 EP EP13862318.6A patent/EP2930176B1/en active Active
- 2013-12-10 PT PT138623186T patent/PT2930176T/pt unknown
- 2013-12-10 SI SI201331009T patent/SI2930176T1/en unknown
- 2013-12-10 MY MYPI2015701868A patent/MY178583A/en unknown
- 2013-12-10 HU HUE13862318A patent/HUE037530T2/hu unknown
- 2013-12-10 MA MA38250A patent/MA38250B1/fr unknown
- 2013-12-10 JP JP2014552040A patent/JP5951799B2/ja active Active
- 2013-12-10 NZ NZ70794613A patent/NZ707946A/en not_active IP Right Cessation
- 2013-12-10 TW TW102145318A patent/TWI615394B/zh active
- 2013-12-10 HR HRP20180647TT patent/HRP20180647T1/hr unknown
- 2013-12-10 AU AU2013358167A patent/AU2013358167B2/en not_active Ceased
- 2013-12-10 PE PE2015000878A patent/PE20151295A1/es active IP Right Grant
- 2013-12-10 WO PCT/JP2013/083022 patent/WO2014092061A1/ja not_active Application Discontinuation
- 2013-12-10 UA UAA201504548A patent/UA115072C2/uk unknown
- 2013-12-10 SG SG11201504204XA patent/SG11201504204XA/en unknown
- 2013-12-10 US US14/426,408 patent/US9428505B2/en active Active
- 2013-12-10 RS RS20180517A patent/RS57190B1/sr unknown
- 2013-12-10 CA CA2892621A patent/CA2892621C/en active Active
- 2013-12-10 CN CN201380064459.1A patent/CN104854106B/zh active Active
- 2013-12-10 ES ES13862318.6T patent/ES2663797T3/es active Active
- 2013-12-10 BR BR112015012411-9A patent/BR112015012411B1/pt active IP Right Grant
- 2013-12-10 LT LTEP13862318.6T patent/LT2930176T/lt unknown
- 2013-12-10 RU RU2015127624A patent/RU2678984C2/ru active
- 2013-12-10 KR KR1020157017844A patent/KR102168738B1/ko not_active Expired - Fee Related
-
2015
- 2015-04-14 IL IL238277A patent/IL238277B/en active IP Right Grant
- 2015-05-21 ZA ZA2015/03597A patent/ZA201503597B/en unknown
- 2015-05-21 CR CR20150272A patent/CR20150272A/es unknown
- 2015-05-22 CL CL2015001391A patent/CL2015001391A1/es unknown
- 2015-05-22 PH PH12015501146A patent/PH12015501146B1/en unknown
- 2015-06-04 SA SA515360528A patent/SA515360528B1/ar unknown
-
2016
- 2016-07-20 US US15/214,729 patent/US20160326175A1/en not_active Abandoned
-
2017
- 2017-01-11 CL CL2017000069A patent/CL2017000069A1/es unknown
- 2017-12-20 US US15/848,267 patent/US20180237436A1/en not_active Abandoned
-
2020
- 2020-02-28 US US16/805,204 patent/US20210024524A1/en not_active Abandoned
-
2021
- 2021-05-25 US US17/330,200 patent/US20220162208A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050101574A1 (en) | 2000-08-30 | 2005-05-12 | Seiichi Ishizuka | Parathyroid hormone production inhibitors containing vitamin d3 derivatives |
| WO2010126030A1 (ja) | 2009-04-28 | 2010-11-04 | 中外製薬株式会社 | スピロイミダゾロン誘導体 |
| US20120270838A1 (en) | 2009-04-28 | 2012-10-25 | Chugai Seiyaku Kabushiki Kaisha | Spiroimidazolone derivative |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102168738B1 (ko) | 히단토인 유도체 | |
| WO2021068898A1 (zh) | 新颖的kras g12c蛋白抑制剂及其制备方法和用途 | |
| US20070275990A1 (en) | Heterocyclic Spiro Compound | |
| US8476293B2 (en) | Tricyclic compound and use thereof | |
| US20070099938A1 (en) | Antistress drug and medical use thereof | |
| ES2982890T3 (es) | Antagonistas del receptor muscarínico de acetilcolina M4 | |
| US20080249154A1 (en) | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | |
| CN106905322A (zh) | 吡咯嘧啶五元氮杂环衍生物及其应用 | |
| US10501466B2 (en) | WDR5 inhibitors and modulators | |
| CN117980305A (zh) | 表现出mnk抑制作用的螺环吡啶-1,5-二酮及其使用方法 | |
| KR102266021B1 (ko) | 히단토인 유도체 함유 의약 조성물 | |
| TWI686392B (zh) | 含有乙內醯脲衍生物之醫藥組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20241017 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20241017 |